BIOXCEL THERAPEUTICS, INC.

IGALMI

Manufacturer:

BIOXCEL THERAPEUTICS, INC.

Igalmi HCPCS:

J1105

HCPCS Code Descriptor:

Dexmedetomidine, oral, 1 mcg

Category:

J Code

Igalmi NDCs:

81092-1120-01, 81092-1180-01

Primary Type:

Psychiatric

Generic/Specialty Status:

Single-Source

Route of Administration:

Sublingual

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Igalmi:

IGALMI is a Psychiatric drug manufactured by BIOXCEL THERAPEUTICS, INC. and administered via the Sublingual route of administration. The J Code: J1105 is aligned to the drug IGALMI.

Igalmi is a form dexmedetomidine used to treat agitation in patients with schizophrenia or bipolar disorder. Igalmi comes in the form of a film that is placed either under the tongue or inside the lower lip. It comes in two doses for a variety of agitation levels.

ACCESS PRICING AND MORE BY REGISTERING

J1105 Added Date:

January 1, 2024

J1105 Effective Date:

January 1, 2024

J1105 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Igalmi billing and coding information.
Igalmi patient assistance information can be found through BioXcel Therapeutics at the URL: https://www.igalmihcp.com/resources
IGALMI prescribing information can be found at the link below:
Information regarding IGALMI’s side effects can be found at MedlinePlus